Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014 in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumors. Ipsen also has a significant presence in primary care. The Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative technological platforms, peptides and toxins, located in the heart of the leading biotechnological hubs (Les Ulis, Fr ; Slough/Oxford, UK ; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million (about 15% of Group sales). The Group has more than 4,500 employees.
Type
Public
HQ
Boulogne Billancourt, FR
Founded
1929
Size (employees)
4,635 (est)
Website
ipsen.com
Ipsen was founded in 1929 and is headquartered in Boulogne-Billancourt, FR

Ipsen Office Locations

Ipsen has an office in Boulogne-Billancourt
Boulogne Billancourt, FR (HQ)
65 Quai Georges Gorse

Ipsen Metrics

Ipsen Market Value History

Ipsen Online Presence

Ipsen News

Ipsen Company Life

You may also be interested in